Sinovac maintains lead as pioneering hand, foot and mouth vaccine moves to Phase III
This article was originally published in Scrip
Based on positive top-line results from a Phase II trial, Sinovac Biotech is preparing to take its vaccine for a serious form of human hand, foot and mouth disease (HFMD) into a multi-centre Phase III programme in China over the next few months.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.